Skip to search formSkip to main contentSkip to account menu

Bethesda units

Known as: BU, Bethesda Unit, [beth'U] 
A unit of measurement for blood coagulation inhibitor activity, expressed in the amount of an inhibitor neutralizing 50% of a coagulant during the… 
National Institutes of Health

Related topics

Related topics

1 relation
Clinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Bortezomib: Potential Key Role in the Treatment of Multiple Myeloma-Related Acquired Hemophilia A
As previously reviewed in this journal, acquired hemophilia A (AHA) is a rare autoimmune disorder due to autoantibodies against… 
2013
2013
Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
2010
2010
The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction
Summary The development of alloantibodies that inhibit or neutralise the function of factor VIII is considered the most serious… 
Review
2009
Review
2009
Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation.
We report the results of external quality assessment exercises in which 60 to 120 centers performed factor VIII (FVIII) inhibitor… 
2001
2001
Heart transplant in a factor VIII‐deficient patient with a high‐titre inhibitor: perioperative management using high‐dose continuous infusion factor VIII and recombinant factor VIIa
Four years prior to transplantation, a 14‐year‐old boy with severe haemophilia A and a high‐responding factor VIII (FVIII… 
1999
1999
Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors
We report on 11 patients (nine unrelated and a brother pair) with severe haemophilia A and factor VIII (FVIII) inhibitor, in whom… 
1999
1999
Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia
Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia 
1997
1997
Factor IX inhibitors and anaphylaxis in hemophilia B.
1995
1995
Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.
1995
1995
Factor VIII inhibitor developed in a 60-year-old patient with mild hemophilia A after surgery for colon cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)